An 82-year-old resident with stable NYHA Class III heart failure, chronic kidney disease (Stage 3), and osteoarthritis is prescribed meloxicam 15 mg daily for knee pain. The consultant pharmacist's primary concern with this new order should be the increased risk of:
-
A
Hepatotoxicity and elevated liver enzymes.
-
B
Worsening fluid retention and acute renal impairment.
-
C
Opioid-sparing effect leading to sedation.
-
D
Drug-induced lupus erythematosus.